Delta Financial Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-5
Closed -$4K 228
2023
Q3
$4K Hold
5
﹤0.01% 210
2023
Q2
$24K Hold
5
0.03% 86
2023
Q1
$14K Hold
5
0.01% 182
2022
Q4
$14K Buy
+5
New +$17.4K 0.01% 176

Other funds holding SEEL

Delta Financial Group's SEEL Position: Q4 2023 in Review

Delta Financial Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 5 shares — an estimated $4K sold.

Delta Financial Group first reported a position in SEEL in Q4 2022 and held it in 4 quarters. The position peaked at $24K in Q2 2023. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

  • Delta Financial Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Delta Financial Group sold 5 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $4K.
  • Delta Financial Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • Delta Financial Group's Seelos Therapeutics, Inc. Common Stock position peaked at $24K in Q2 2023.
  • 32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Delta Financial Group's 13F filing for Q4 2023, filed 18 Jan 2024.